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Cannabis use and the risk of tuberculosis: a
systematic review
Clare E. French1,2†, Caroline M. Coope2,3*†, Luke A. McGuinness1,2, Charles R. Beck2,3, Sophie Newitt4,
Lauren Ahyow5, Matt Hickman1,2 and Isabel Oliver2,3
Abstract
Background: Cannabis has been identified as a possible risk factor in some tuberculosis (TB) outbreaks. As the
most widely used (largely) illegal substance in Western countries this may be an important public health concern.
We aim to systematically review the evidence on the association between cannabis use and TB (latent infection
and active disease) to inform ongoing and future TB prevention and control strategies.
Methods: We conducted a systematic review. We searched Ovid Medline, Embase and PsycInfo, together with the
World Health Organization website and Google Scholar, for all years to January 2018. Reference lists and conference
abstracts were hand-searched, a forward citation search was conducted on the Web of Science, and experts were
contacted. Two authors independently screened studies for inclusion, extracted data and assessed risk of bias using
an adapted version of ROBINS-I (“Risk of Bias in Non-randomised Studies – of Interventions”). Data were narratively
synthesised.
Results: Of 377 records identified, 11 studies were eligible. Study designs were heterogeneous. Six studies utilised a
relevant comparator group. Four of these investigated the association between cannabis use and latent TB
infection; all provided some evidence of an association, although only two of these had adjusted for confounders.
The remaining two comparator studies investigated the association between cannabis use and active TB disease;
neither found evidence of an association after adjusting for confounding. All six studies were at “Serious” risk of
bias. The five studies which did not utilise a relevant comparator group were all indicative of TB outbreaks
occurring among cannabis users, but the quality of the evidence was very weak.
Conclusions: Evidence for an association between cannabis use and TB acquisition is weak. The topic warrants
further robust primary research including the collection of consistent and accurate exposure information, including
cannabis use practices, dose and frequency, and adjustment for confounders.
Keywords: Tuberculosis, Cannabis, Systematic review, Evidence synthesis
Background
It is estimated that 1.7 billion people are infected with
Mycobacterium tuberculosis (TB) globally of which 5 to
15% will develop active TB disease, depending on co-
existing risk factors such as under-nutrition, diabetes, HIV
(human immunodeficiency virus) infection, smoking and
alcohol consumption [1]. In high-income countries TB
has most commonly occurred in marginalised populations
such as migrants, the homeless, people who inject drugs
and prisoners [2–4]. With the introduction of whole gen-
ome sequencing in TB outbreak investigation the accurate
linkage of cases, even prior to epidemiological linkage [5],
has facilitated the identification of previously unrecog-
nised risk factors for transmission. These novel risk fac-
tors, such as cannabis use, may be important to inform
outbreak investigations and control efforts and need to be
better understood.
Cannabis is estimated to be the most widely used
(largely) illegal substance in Western countries including
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Europe [6], North America [7] and Australia [8]. Fre-
quent cannabis use has been reported among cases in
previous TB outbreaks [9, 10], and recently in an out-
break of pulmonary TB in the United Kingdom (UK) in
which 26% of those with latent TB infection (LTBI) and
67% with TB disease reported cannabis smoking (Lauren
Ahyow, Public Health England – personal communica-
tion). Given the prevalence of cannabis use, and the in-
creasing potency available [6], there is a pressing need to
understand whether there is an association between can-
nabis use and TB - a potentially significant public health
concern.
The method used to inhale cannabis could be import-
ant in TB transmission and links have been found with
sharing a cannabis water pipe or ‘bong’ [11] and ‘shot-
gunning’ (the practice of inhaling smoke and then exhal-
ing it into another individual’s mouth) [12]. These
behaviours may offer an environment for the efficient
transmission of TB, such as prolonged exposure and
close proximity to a case. Evidence supports the bio-
logical plausibility of an association as heavy cannabis
smoking has been associated with chronic bronchitis
symptoms and large airway inflammation which may
lower the lungs natural defences against infection [13].
Additionally, there is evidence that tobacco smoking,
often adjunct to cannabis use, is associated with TB in-
fection and disease [14] and may increase the risk of dis-
ease by as much as 2.5 times [15].
To our knowledge, evidence on the possible associ-
ation between cannabis use and TB infection and disease
has not been systematically reviewed. We aim to address
this gap to inform ongoing and future TB prevention
and control strategies.
Methods
This review is reported in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [16]. The review protocol can be ob-
tained by request from the corresponding author.
Eligibility criteria
All types of primary epidemiological studies (e.g. descrip-
tive studies, outbreak reports, cohort studies, case-control
studies) were eligible for inclusion. The review question
was structured using a PECO framework as follows:-
Population: adults aged ≥16 years; Exposure: cannabis use
by any means; Comparator: any e.g. no reported cannabis
use, no comparator; Outcome: active TB disease affecting
any clinical site (pulmonary or extra-pulmonary) or latent
infection e.g. assessed by Tuberculin Skin Testing [TST]
(‘Mantoux’ test) or an interferon-gamma release assay. No
restriction was placed on the type/availability of a specific
comparator group in order that the complete body of evi-
dence could be reviewed.
Search strategy
Electronic searches were conducted in Ovid Medline,
Embase and PsycInfo, from the inception of each data-
base to 17 January 2018. Subject Headings (MeSH,
EMTREE, APA) and free-text key words were used (see
Additional file 1 for search terms). No restriction was
placed on language or publication status. The World
Health Organization website and Google Scholar were
searched. We also checked abstract lists for the annual
Union World Conference on Lung Health for the years
2015–2017. Reference lists of eligible studies were hand-
searched, and a forward citation search was conducted
in Web of Science to help identify follow-up studies or
new research citing any of the study reports included in
the review. Experts in the field were contacted to iden-
tify any further published or unpublished studies. Re-
cords were stored and managed in EndNote X9.
Study selection
Two authors screened studies for eligibility and agreed the
final list for inclusion. Reasons for exclusion of studies that
reached the full-text screening stage were documented.
Data extraction and synthesis
Data from eligible studies was double extracted by two
reviewers (CEF and CMC) using a pre-defined form, and
cross-checked. Key data items (as listed in Table 1) were
extracted and narratively synthesized. Summary mea-
sures reported varied; we extracted odds ratios (e.g.
comparing the odds of TB in those who reported using
cannabis vs. those who did not) whenever documented.
Studies which utilised a relevant comparator group are
reported separately from those which did not. Given the
substantial heterogeneity between studies it was not ap-
propriate to perform a meta-analysis.
Risk of bias assessments
Risk of bias was assessed for studies which utilised a
comparator group. Each distinct result from these stud-
ies was assessed across six risk of bias domains using an
adapted version of the ROBINS-I tool (“Risk of Bias in
Non-randomised Studies – of Interventions”), [17] in-
formed by the preliminary ROBINS-E tool (“Risk of Bias
In Non-randomised Studies – of Exposure”) [18]. Al-
though ROBINS-I is designed to assess risk of bias in
intervention studies many of the domains are relevant to
non-randomised studies of exposures. Summary level
judgements were made for each domain and were used
to inform an overall risk of bias judgement (see Add-
itional file 2 for guidance used to make domain level risk
of bias judgements).
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Results
Description of studies
After removal of duplicates, the initial electronic searches
identified 373 potentially eligible records, with four add-
itional eligible records identified from other sources. After
screening, 11 studies fit the criteria for inclusion in the re-
view (Fig. 1). These originated from the United States
(six), Australia (three), the UK (one) and Kazakhstan (one)
. Study designs were heterogeneous. Six studies utilised a
relevant comparator group [9, 11, 19–22]. Of these, two
were retrospective cohort studies of TB outbreaks [9, 11],
two used routinely collected data [19, 21], one was a
matched case-control study [20], and one a case series
study that included a retrospective cohort study of con-
tacts [22]. These six studies contributed seven effect esti-
mates, as Davis et al [20] contributed two separate results.
Of the remaining five studies four were descriptive out-
break reports/investigations [10, 23–25] and one was an
analytic study [26] where the outcome of interest was hav-
ing TB disease from which a specific strain of TB was
isolated (as compared with having TB caused by a differ-
ent strain) (Table 1).
Risk of bias in studies which utilised a relevant
comparator group
Risk of bias assessments for each of the six studies which
used a comparator group are presented in Table 2. All
seven results (reported by the six studies) were judged to
be at “Serious” risk of bias overall. These overall “Serious”
judgments were largely due to the ‘Bias due to confound-
ing’ domain, ‘Bias in selection of participants into the
study’ domain, and the ‘Bias in measurement of outcomes’
domain. Two studies were at “Serious” risk of bias due to
the extent of missing data.
Results of studies which utilised a relevant comparator
group (Table 1)
Cannabis use as a risk factor for latent TB
Four studies reported on the association between canna-
bis use and the risk of latent TB. Morano et al analysed
Sift at title/abstract
(n=373)
Records identified via electronic 
database searches 
(n=442)
Duplicates removed (n=69)
Reject at title/abstract (n=362)
Sift at full text
(n=11)
Eligible for inclusion
(n=11)
Reject at full text - no data on  
cannabis use as a risk factor for 
TB (n=4)
Citation search of eligible study 
reports (195 retrieved, 0 eligible)
Additional eligible records 
identified
Reference lists of eligible study 
reports: 3
Conference abstracts: 1
Contacting experts: 0
Fig. 1 Study selection flow chart
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data routinely collected by a mobile medical clinic and
found cannabis use (‘ever’) to be associated with incident
(but not prevalent) latent TB infection after adjustment
for confounders (adjusted odds ratio [aOR]: 1.57; 95%
confidence interval [CI]:1.05–2.37) [21].
One retrospective cohort study [11] and one retro-
spective case series combined with a retrospective co-
hort study of contacts [22] assessed the association
between sharing a cannabis bong with a TB case and the
odds of having latent TB. In the cohort study of 149
identified contacts, 45 had shared a cannabis bong with
a case. The aOR for latent TB in those who shared a
bong with a pulmonary TB case vs. those who had not
was 2.22 (95% CI:0.96–5.17). In this cluster, cannabis
smoking was frequently performed in closed rooms or
cars. The authors noted that it was not possible to disag-
gregate relative contributions of sharing a bong and pro-
longed confinement in a shared airspace [11]. In the
case series all three cases were young adults who re-
ported regularly smoking cannabis through a bong. Of
111 contacts screened, 34 were positive for latent TB
(positive TST), one of whom developed active TB. Con-
tacts who shared a bong with an active TB case (n = 7)
had a six-fold risk of a positive TST (OR 6.5, 95% CI:
1.4–30.4, p = 0.016), though there was no adjustment for
confounders [22].
One retrospective cohort study reviewed the association
between being a member of a closely connected network
of young men ‘friends’ who exhibited similar cannabis
using behaviour [9]. There were 11 culture-confirmed
cases (8 were sputum acid-fast bacilli (AFB) sputum smear
positive), all of whom reported frequent ‘hotboxing’
(smoking cannabis in a confined space, such as a car, to
maximise the effect [27]). The risk ratio of positive TST in
the ‘friends’ contacts vs. other contacts was 2.8 (95% CI:
1.3–6.0). Contacts with a past positive TST result were ex-
cluded from the analyses but no adjustment was made for
confounding.
Cannabis use as a risk factor for active TB disease
Two studies reported on the association between canna-
bis use and having active TB disease. An analysis of rou-
tinely collected data found no evidence that cannabis
use was associated with the risk of ever being diagnosed
with TB disease; using those who had never used canna-
bis as the reference, the aORs were 0.79 (95% CI:0.33–
1.87) for those with ≤1 year use, 0.72 (95% CI:0.25–2.06)
for those with 2–10 years use, and 0.73 (95% CI:0.60–
3.28) for those with ≥11 years use [19]. A matched
case-control study also demonstrated that after adjust-
ment for confounding factors there was no statistical
evidence of an association with ever having used canna-
bis and recent TB disease (aOR:1.64, 95% CI:0.76–3.54,
p = 0.210 [20].
Results of studies which did not utilise a relevant
comparator group (Table 1)
Cannabis use as a risk factor for latent TB
Livengood et al conducted an investigation of contacts
of a patient with culture and AFB sputum smear positive
isoniazid-resistant TB [23]. Cannabis use was identified
as the most important social risk factor for TB transmis-
sion - 100% (14/14) of those contacts who used cannabis
had a positive TST result. The authors report that the
practice of ‘hotboxing’ undoubtedly contributed to TB
transmission.
Cannabis use as a risk factor for active TB disease
Four studies reported on cannabis use as a risk factor
for active TB disease. Merritt et al characterised a cluster
of nine cases and two probable cases of pulmonary TB
[24]. Cannabis use was identified in 67% (6/9) of con-
firmed cases and both the suspected cases. Authors state
that use of shared smoking equipment was not explored.
Sterling et al reported on a TB outbreak among a
highly mobile population in the US. The index case had
AFB smear positive pulmonary disease. Twenty outbreak
Table 2 Risk of bias assessments
Author, year Domain-level judgments Overall
judgementBias due to
confounding
Bias in selection
of participants
into the study
Bias in
classification
of exposures
Bias due to
missing data
Bias in
measurement
of outcomes
Bias in selection
of the reported
result
Morano, 2014 [21] Moderate Moderate Moderate Serious Moderate Moderate Serious
Munckhof, 2003 [11] Moderate Serious Moderate Serious Low Moderate Serious
Thu, 2014 [22] Serious Serious Moderate No information Low Moderate Serious
Oeltmann, 2006 [9] Serious Serious Moderate No information Low Moderate Serious
Han, 2010 [19] Moderate Moderate Moderate No information Serious Moderate Serious
Davis, 2017a [20] Moderate Low Moderate No information Serious Moderate Serious
Davis, 2017b [20] Serious Low Moderate No information Serious Moderate Serious
a Ever used cannabis
b Cannabis use within last 90 days
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cases were identified, 35% of whom (n = 7) reported can-
nabis use [10].
Evans et al reviewed the association between cannabis
use and having a specific TB strain by examining the
epidemiological characteristics of culture-positive TB
cases with an indistinguishable MIRU-VNTR profile (the
“Mercian” strain) [26]. Eleven of the 35 cases (31%) with
the Mercian strain reported cannabis use compared with
2/47 (4%) with other TB strains (OR: 10.02, 95% CI:
1.96–100.3, p < 0.01).
Finally, McElroy et al investigated a cluster of 22
outbreak-associated TB patients (including 19 adults);
79% of the 19 active TB cases reported cannabis use,
compared with 35% of a convenience sample of primary
contacts (33% of those TST positive and 36% of those
TST negative). Sputum AFB status was reported for fe-
male cases (n = 9) only; seven had smear-positive cavi-
tary pulmonary TB [25].
Discussion
We found 11 studies investigating the association between
cannabis use and TB infection or disease. All studies were
observational and most originated from high-income set-
tings (10/11 studies). Six studies utilised a relevant com-
parator group. Four of these investigated the association
between cannabis use and latent TB infection; all provided
some evidence of an association, although only two of these
had adjusted for confounders. The remaining two compara-
tor studies investigated the association between cannabis
use and active TB disease; neither found evidence of an as-
sociation after adjusting for confounding. Five studies did
not utilise a relevant comparator group; all indicated that
TB outbreaks do occur among cannabis users but were not
designed to test for an association.
Overall the quality of the evidence was weak and of in-
sufficient quality to reliably quantify the risk. There was
heterogeneity across populations studied and approaches
to data analysis. Description of the exposure in terms of
type and quantity, frequency, timing and method of can-
nabis use was largely inadequate. All six comparative
studies were assessed as being at “Serious” risk of bias.
Three of the seven results obtained from the six studies
did not adjust for confounding. This may be indicative
of the contexts in which studies were conducted - three
emanated from outbreak investigations and the remain-
der utilised existing data sources not specifically de-
signed to test this hypothesis. Where confounding
variables were adjusted for these were heterogeneous
across studies. Three results were assessed as being at
“Serious” risk of ‘bias in the measurement of outcomes’,
e.g. because investigators relied on self-reported TB sta-
tus. In general, there was a lack of clear and sufficiently
comprehensive information reported – e.g. for five of
the seven results we could not assess ‘bias due to
missing data’ as no relevant data was available. It is im-
portant that the poor quality of the available studies,
with respect to addressing the review question, is borne
in mind and care taken not to over interpret the data
presented in this review.
The exposure and outcome measures used were not al-
ways appropriate for assessing an association between can-
nabis use and TB. For instance, several studies recorded the
exposure as ‘ever used’ cannabis or the outcome as ‘ever’
having a diagnosis of TB. We felt it appropriate to include
such studies in the review, particularly given the paucity of
evidence but note that any association between cannabis
and TB will likely differ depending on whether use is
current or past and whether cannabis use preceded TB
diagnosis. Additionally, studies lacked information on
whether cannabis was used alone or with tobacco. Smoking
tobacco is known to be associated with TB risk [15]. Prac-
tice varies globally - cannabis is commonly mixed with to-
bacco in Europe but is much more likely used alone in the
US, while in Australia both practices are equally used [28].
Most studies in this review originated from the US (six),
followed by Australia (three). These studies, particularly
those from the US, and the two from Australia reporting
on cannabis smoking via a water pipe, are therefore likely
to provide some evidence, though not necessarily exclu-
sively, relating to the specific effect of cannabis (rather than
tobacco, or the combination of the two) on TB risk.
The aim of this review was to establish whether there
is evidence of an association between cannabis use and
TB acquisition, rather than to elicit the mechanisms by
which any such association might operate. Indeed, with
the evidence available it is not possible to disentangle
the relative contributions of TB transmission being facil-
itated via close contact/shared air space (e.g. via ‘hotbox-
ing’), the spread of TB via contaminated equipment (e.g.
via shared water pipes) or cannabis use as a more gen-
eral social risk factor for TB, as compared with the po-
tential biological or physiological mechanisms through
which the act of inhaling cannabis may itself increase
susceptibility to TB (e.g. through damage to the lungs).
The presence of AFB in the sputum is an important
risk factor for onward transmission of TB [29, 30]. None
of the studies in this review directly investigated whether
sputum smear status influenced the association between
cannabis use and TB. However, of the six studies which
used a relevant comparator group, three reported that
either all or most of the active TB cases were AFB smear
positive. All of these three studies reported some evi-
dence of an association between cannabis use and TB
acquisition [9, 11, 22].
Strengths and limitations of the review process
We conducted a comprehensive literature search, with
no language or date restrictions in order to ensure, as
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far as possible, that we identified all relevant studies.
Though not a limitation of the review process as such,
we note that publication bias is a potential concern –
outbreak investigations are primarily purposed for dis-
ease control and many remain unpublished in any form,
particularly if there are no unusual findings. Two au-
thors independently assessed each study for eligibility,
extracted the data and conducted the risk of bias assess-
ments. This approach will have helped minimise both er-
rors and potential biases in the review process.
ROBINS-I is a comprehensive published tool for asses-
sing risk of bias in non-randomised studies. Since the tool
is not specifically designed for assessing studies of expo-
sures, we recognise that it may be limited in its ability to ac-
curately classify the risk of bias in such studies. To help
mitigate this we performed assessments at the domain level
without answering the intra-domain signalling questions
that are tailored to assessing intervention studies. We also
used brief preliminary guidance for the forthcoming
ROBINS-E tool tailored for studies of exposures. These ap-
proaches should reduce the potential for misclassification
of bias judgements introduced by the inconsistency be-
tween study design and assessment tool. We do, however,
recognise that any such risk of bias assessments may be
open to subjective interpretation particularly where detailed
information about study methodology is not reported, as
was the case for several studies in this review.
Conclusions
The evidence for an association between cannabis use
and TB is weak. We found a lack of studies on the topic,
and those that are available are of poor quality. We
found some evidence for an association between canna-
bis use and latent TB infection, but little evidence for an
association with TB disease. Many of the studies we
reviewed emanated directly from field investigations of
TB clusters and outbreaks including contact tracing,
with the aim to identify the source and transmission
routes to prevent further spread. Consequently, these
were not designed specifically to assess the association
between cannabis use and TB and suffered from bias at
the design, conduct and analysis stages. However, a pos-
sible association between cannabis use and TB has been
indicated in several outbreak investigations and it cannot
be excluded as a possible risk factor based on the
current literature. Indeed this remains an important ques-
tion to answer to inform future outbreak control mea-
sures, especially in light of potential increased cannabis
use in the context of decriminalisation policies [31].
Implications for practice and research
The evidence base on cannabis use and TB needs to be
strengthened. Opportunities exist in the context of whole-
genome sequencing to more accurately distinguish cases
that are part of a recent transmission cluster. The intro-
duction of universal minimum standards for the reporting
of infectious disease outbreaks could help improve the
utility of published outbreak reports and must include ac-
curate and comparable information on exposures, includ-
ing, in this case, cannabis use practices, dose, frequency
and timing. Efforts to facilitate observational epidemio-
logical studies that include cannabis and other key expo-
sures are needed and must include the collection and
adjustment of key confounding factors. Studies designed
to assess the independent association of cannabis use on
TB infection and disease are ultimately required in order
to specify the relative risk of this behaviour in the context
of closely related risk factors such as close proximity and
shared airspace.
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